Krystal Biotech (KRYS) Stock Price
Krystal Biotech Price
Revenue has compounded at 133.5% per year over the past 7 years to 389.13 M USD. Earnings per share have grown at 324.6% per year over the last 2 years. Krystal Biotech's net margin stands at 52.6%, up from -1,060.3% several years earlier. Analysts set a median price target of 380.50 USD, implying 17.2% above the current price. Of 19 analysts, 17 rate the stock a buy — an overall Buy consensus.
Krystal Biotech stock price
Krystal Biotech business model & stock analysis
Frequently asked questions about Krystal Biotech
Krystal Biotech Inc is a biopharmaceutical company specializing in gene therapies. Their business model focuses on developing and commercializing innovative treatments to address severe dermatological diseases. By harnessing the power of gene therapy, Krystal Biotech aims to provide targeted and sustainable solutions for patients, offering potential long-term benefits. With a strong emphasis on cutting-edge research and development, they strive to revolutionize the treatment landscape by creating novel therapies that address unmet medical needs. Krystal Biotech Inc's business model is driven by a commitment to scientific excellence and a passion for improving the lives of patients suffering from dermatological conditions.
Krystal Biotech Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Krystal Biotech Inc in the market include companies such as Regenxbio Inc, bluebird bio Inc, and Sangamo Therapeutics Inc. These companies have a similar focus on gene therapy and are actively engaged in the development and commercialization of innovative treatments for genetic diseases. Krystal Biotech Inc competes with these companies in terms of research, development, and market adoption of gene therapy products.
Krystal Biotech Inc, headquartered in Pittsburgh, Pennsylvania, is a clinical-stage gene therapy company focused on developing and commercializing transformative treatments for patients suffering from rare genetic diseases. Founded in 2015, Krystal Biotech is driven by a mission to deliver potentially curative therapies that address the unmet medical needs of patients worldwide. Leveraging its proprietary Skin TARgeted Delivery platform, the company aims to develop innovative gene therapies for dermatological conditions, starting with its lead product candidate, KB105. Through strategic collaborations, Krystal Biotech strives to revolutionize the treatment landscape by advancing gene therapies to provide hope for patients and their families.
Krystal Biotech Inc has achieved several significant milestones. One of the notable achievements includes the successful completion of the phase 2 clinical trial for their gene therapy product, known as KB103. This product aims to treat a rare skin disorder called dystrophic epidermolysis bullosa (DEB). Additionally, the company has also achieved positive results in pre-clinical trials for other gene therapy candidates, showcasing their potential to address various genetic disorders. Krystal Biotech Inc has received several grants and awards for their innovative research and development efforts. These achievements highlight the promising growth and potential of Krystal Biotech Inc in the field of gene therapy.
Krystal Biotech Inc is primarily present in the United States.
Krystal Biotech Inc represents values of innovation, dedication, and excellence in the field of biotechnology. The company is committed to developing and delivering advanced gene therapies to treat rare skin diseases. With a vision to transform lives, Krystal Biotech focuses on providing effective and safe solutions that address unmet medical needs. Their corporate philosophy revolves around promoting patient-centric care, scientific rigor, and ethical practices. By leveraging cutting-edge technology and scientific expertise, Krystal Biotech strives to enhance the quality of life for individuals affected by genetic skin disorders.
Analysts currently set an average price target of 383.75 USD for the Krystal Biotech stock (median: 380.50 USD), implying +18.2 % versus the latest price. The consensus is based on 19 analyst ratings.
19 analysts currently rate the Krystal Biotech stock: 17 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Krystal Biotech to generate revenue of 507.12 M USD and earnings per share of 7.37 USD.
Converted at the current exchange rate, the Krystal Biotech share trades at 289.60 EUR (324.57 USD).
The Krystal Biotech share (KRYS) is listed on 4 stock exchanges, including: NASDAQ (KRYS), Frankfurt (4KB.F), München (4KB.MU), Düsseldorf (4KB.DU).
Krystal Biotech Inc is a biotechnology company focused on developing gene therapy products for rare dermatology and genetic diseases. The company aims to develop innovative therapies that improve the lives of patients with rare diseases. The business model is based on the development and commercialization of gene therapy products. Krystal Biotech uses a proprietary gene therapy platform called HSV-1 vector to develop therapies for serious and rare dermatological conditions such as Epidermolysis bullosa, Netherton syndrome, and Heidelberg syndrome. The company's gene therapy products utilize the HSV-1 vector's ability to introduce DNA into rapidly dividing cells, such as skin cells, to replace the defective gene causing the disease and restore normal functioning of the affected cells. Krystal Biotech focuses on developing gene therapies for severe and rare diseases where effective treatments are often lacking. The company has several gene therapy products in development, including KB103 for the treatment of Epidermolysis bullosa, KB105 for the treatment of Netherton syndrome, and KB104 for the treatment of Heidelberg syndrome. KB103 is currently in phases 1 and 2 of clinical development and has the potential to become the first approved gene therapy product for treating Epidermolysis bullosa. Krystal Biotech also places a strong emphasis on collaboration with other companies and stakeholders in the biotechnology industry. The company has entered into a collaboration agreement with the international pharmaceutical company Bayer to develop a gene therapy platform for the treatment of serious eye diseases. In summary, Krystal Biotech's business model is based on the development and commercialization of gene therapy products for rare dermatological and genetic diseases. The company aims to improve the lives of patients with severe and rare diseases and seeks partnerships and alliances with other biotechnology companies and stakeholders in the industry to achieve this goal.
The expected revenue of Krystal Biotech is 507.12 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Krystal Biotech is 220.61 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Krystal Biotech is currently 44.06. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Krystal Biotech stock.
The price-to-sales ratio (P/S) of Krystal Biotech is currently 19.17. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Krystal Biotech stock.
The Eulerpool Quality Score for Krystal Biotech is 5/10.
The ISIN of Krystal Biotech is US5011471027. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Krystal Biotech is A2JH2F. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Krystal Biotech is KRYS. The ticker symbol is used to trade Krystal Biotech shares on the stock exchange.
Krystal Biotech stock
Krystal Biotech Peer Group
Krystal Biotech Ticker
Krystal Biotech FIGI
All fundamentals and in-depth analysis of Krystal Biotech
Our stock analysis for Krystal Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Krystal Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.